CN Patent

CN114957236B — 一种2-酰基氨基噻唑类化合物的制备方法

Assigned to Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd · Expires 2026-02-03 · 0y expired

What this patent protects

本发明涉及一种2－酰基氨基噻唑类化合物的制备方法，具体涉及一类阿伐曲泊帕中间体的制备方法，在该制备工艺中，使用四氢呋喃与DMSO的混合溶液做溶剂，使反应形成均相体系，进而使得该制备方法具有后处理简单、收率高和产品纯度高等优点，而且所采用的方法尤其适合工业化生产。

USPTO Abstract

本发明涉及一种2－酰基氨基噻唑类化合物的制备方法，具体涉及一类阿伐曲泊帕中间体的制备方法，在该制备工艺中，使用四氢呋喃与DMSO的混合溶液做溶剂，使反应形成均相体系，进而使得该制备方法具有后处理简单、收率高和产品纯度高等优点，而且所采用的方法尤其适合工业化生产。

Drugs covered by this patent

dordaviprone-hydrochloride (DORDAVIPRONE HYDROCHLORIDE)

Patent Metadata

Patent number: CN114957236B
Jurisdiction: CN
Classification: —
Expires: 2026-02-03
Drug substance claim: No
Drug product claim: No
Assignee: Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.